Ozarelix clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses ozarelix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Ozarelix
- 3
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses ozarelix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)TerminatedPhase 2Spectrum Pharmaceuticals, IncNCT00743184Written as ozarelixHow we know
- The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the ProstateCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00427219Written as OzarelixHow we know
- International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate CancerCompletedPhase 2Spectrum Pharmaceuticals, IncNCT01252693Written as OzarelixHow we know
Codes
What other systems call ozarelix · ClinicalTrials.gg INT005791
- MeSH (NLM) C556865ozarelixOne source NLM
- UNII (FDA) Q1IF8M2YL3OZARELIXConfirmed FDA, NLM, Wikidata
- Wikidata Q27286888ozarelixConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95214OzarelixOne source FDA
- DrugBank DB12581One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C556865 | ozarelix | One source NLM |
| UNII (FDA) | Q1IF8M2YL3 | OZARELIX | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27286888 | ozarelix | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95214 | Ozarelix | One source FDA |
| DrugBank | DB12581 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.